This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
25 Apr 2012

Harlan & Ipsen Ink Drug Development Services Deal

The two companies have entered into a three-year programme on the development of early preclinical stage drug candidates.

Harlan Laboratories Contract Research Services (CRS) and Ipsen have entered into a three-year programme on the development of early preclinical stage drug candidates with exclusivity in some specific areas.

 

As a result, Harlan Laboratories says it has consolidated its standing in the early stage of the drug development process and has established itself as a leader in preclinical drug development.

 

"This new agreement with Ipsen is in line with our strategy to satisfy the needs of the pharmaceutical industry in the preclinical arena," said Dr Ciriaco Maraschiello, head of global general toxicology, Harlan Laboratories CRS.

 

Related News